Reverse Innovation In China: An Interview With HUYA CEO Mireille Gillings
This article was originally published in PharmAsia News
Eight years ago, HUYA’s CEO Mireille Gillings began screening compounds developed in China to bring them to global markets. Nowadays, the company says it has a database with more than 12,000 compounds and 2,000 biomarkers from China.
You may also be interested in...
San Diego's Huya Signs Six New Deals With Chinese Scientific Partners, Looks To Fast Forward Global Drug Development
BEIJING - During a whirlwind tour of China, the leaders of the San Diego-headquartered Huya Bioscience have signed, in rapid succession, partnership pacts with prestigious scientific institutions in half a dozen cities on drug research and development
SHANGHAI - Huya Bioscience International has entered into a strategic alliance to help accelerate the development of innovative R&D projects originating in China Medical City, in the Taizhou National Medical Hi-tech Development Zone
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.